<?xml version="1.0" encoding="UTF-8"?>
<xml><records><record><database name="MyLibrary">MyLibrary</database><source-app name="Zotero">Zotero</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lewnard, Joseph A.</author><author>Hong, Vennis X.</author><author>Patel, Manish M.</author><author>Kahn, Rebecca</author><author>Lipsitch, Marc</author><author>Tartof, Sara Y.</author></authors></contributors><titles><title>Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California</title><secondary-title>Nature Medicine</secondary-title></titles><periodical><full-title>Nature Medicine</full-title><abbr-1>Nat Med</abbr-1></periodical><pages>1-1</pages><keywords><keyword>Epidemiology</keyword><keyword>Viral infection</keyword></keywords><dates><year>2022</year><pub-dates><date>2022-06-08</date></pub-dates></dates><isbn>1546-170X</isbn><electronic-resource-num>10.1038/s41591-022-01887-z</electronic-resource-num><abstract>Epidemiologic surveillance has revealed decoupling of COVID-19 hospitalizations and deaths from case counts following emergence of the Omicron (B.1.1.529) SARS-CoV-2 variant globally. However, assessment of the relative severity of Omicron variant infections presents challenges because of differential acquired immune protection against Omicron and prior variants, and because longer-term changes have occurred in testing and healthcare practices. Here we show that Omicron variant infections were associated with substantially reduced risk of progression to severe clinical outcomes relative to time-matched Delta (B.1.617.2) variant infections within a large, integrated healthcare system in southern California. Adjusted hazard ratios (aHRs) for any hospital admission, symptomatic hospital admission, intensive care unit admission, mechanical ventilation, and death comparing cases with Omicron versus Delta variant infection were 0.59 (95% confidence interval: 0.51-0.69), 0.59 (0.51-0.68), 0.50 (0.29-0.87), 0.36 (0.18-0.72), and 0.21 (0.10-0.44) respectively. This reduced severity could not be explained by differential history of prior infection among cases with Omicron or Delta variant infection, and was starkest among cases not previously vaccinated against COVID-19 (aHR=0.40 [0.33-0.49] for any hospital admission and 0.14 [0.07-0.28] for death). Infections with the Omicron BA.2 subvariant were not associated with differential risk of severe outcomes in comparison to BA.1/BA.1.1 subvariant infections. Lower risk of severe clinical outcomes among cases with Omicron variant infection should inform public health response amid establishment of the Omicron variant as the dominant SARS-CoV-2 lineage globally.</abstract><remote-database-name>www.nature.com</remote-database-name><language>en</language><urls><web-urls><url>https://www.nature.com/articles/s41591-022-01887-z</url></web-urls><pdf-urls><url>C:\Users\bcalverley\Zotero\storage\V6JAE5TM\Lewnard et al__Clinical outcomes associated with SARS-CoV-2 Omicron (B__2022.pdf</url></pdf-urls><text-urls><url>C:\Users\bcalverley\Zotero\storage\5QAFR7VE\s41591-022-01887-z.html</url></text-urls></urls><access-date>2022-07-22 21:39:44</access-date></record><record><database name="MyLibrary">MyLibrary</database><source-app name="Zotero">Zotero</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Shrestha, Lok Bahadur</author><author>Foster, Charles</author><author>Rawlinson, William</author><author>Tedla, Nicodemus</author><author>Bull, Rowena A.</author></authors></contributors><titles><title>Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission</title><secondary-title>Reviews in Medical Virology</secondary-title><short-title>Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5</short-title></titles><periodical><full-title>Reviews in Medical Virology</full-title><abbr-1>Rev Med Virol</abbr-1></periodical><pages>e2381</pages><keywords><keyword>immune evasion</keyword><keyword>monoclonal antibodies</keyword><keyword>omicron</keyword><keyword>SARS-COV-2</keyword></keywords><dates><year>2022</year><pub-dates><date>2022-07-20</date></pub-dates></dates><isbn>1099-1654</isbn><electronic-resource-num>10.1002/rmv.2381</electronic-resource-num><abstract>The first dominant SARS-CoV-2 Omicron variant BA.1 harbours 35 mutations in its Spike protein from the original SARS-CoV-2 variant that emerged late 2019. Soon after its discovery, BA.1 rapidly emerged to become the dominant variant worldwide and has since evolved into several variants. Omicron is of major public health concern owing to its high infectivity and antibody evasion. This review article examines the theories that have been proposed on the evolution of Omicron including zoonotic spillage, infection in immunocompromised individuals and cryptic spread in the community without being diagnosed. Added to the complexity of Omicron's evolution are the multiple reports of recombination events occurring between co-circulating variants of Omicron with Delta and other variants such as XE. Current literature suggests that the combination of the novel mutations in Omicron has resulted in the variant having higher infectivity than the original Wuhan-Hu-1 and Delta variant. However, severity is believed to be less owing to the reduced syncytia formation and lower multiplication in the human lung tissue. Perhaps most challenging is that several studies indicate that the efficacy of the available vaccines have been reduced against Omicron variant (8-127 times reduction) as compared to the Wuhan-Hu-1 variant. The administration of booster vaccine, however, compensates with the reduction and improves the efficacy by 12-35 fold. Concerningly though, the broadly neutralising monoclonal antibodies, including those approved by FDA for therapeutic use against previous SARS-CoV-2 variants, are mostly ineffective against Omicron with the exception of Sotrovimab and recent reports suggest that the Omicron BA.2 is also resistant to Sotrovimab. Currently two new Omicron variants BA.4 and BA.5 are emerging and are reported to be more transmissible and resistant to immunity generated by previous variants including Omicron BA.1 and most monoclonal antibodies. As new variants of SARS-CoV-2 will likely continue to emerge it is important that the evolution, and biological consequences of new mutations, in existing variants be well understood.</abstract><remote-database-name>PubMed</remote-database-name><language>eng</language><urls><text-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/35856385</url></text-urls></urls></record><record><database name="MyLibrary">MyLibrary</database><source-app name="Zotero">Zotero</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Karthikeyan, Smruthi</author><author>Levy, Joshua I.</author><author>De Hoff, Peter</author><author>Humphrey, Greg</author><author>Birmingham, Amanda</author><author>Jepsen, Kristen</author><author>Farmer, Sawyer</author><author>Tubb, Helena M.</author><author>Valles, Tommy</author><author>Tribelhorn, Caitlin E.</author><author>Tsai, Rebecca</author><author>Aigner, Stefan</author><author>Sathe, Shashank</author><author>Moshiri, Niema</author><author>Henson, Benjamin</author><author>Mark, Adam M.</author><author>Hakim, Abbas</author><author>Baer, Nathan A.</author><author>Barber, Tom</author><author>Belda-Ferre, Pedro</author><author>Chac√≥n, Marisol</author><author>Cheung, Willi</author><author>Cresini, Evelyn S.</author><author>Eisner, Emily R.</author><author>Lastrella, Alma L.</author><author>Lawrence, Elijah S.</author><author>Marotz, Clarisse A.</author><author>Ngo, Toan T.</author><author>Ostrander, Tyler</author><author>Plascencia, Ashley</author><author>Salido, Rodolfo A.</author><author>Seaver, Phoebe</author><author>Smoot, Elizabeth W.</author><author>McDonald, Daniel</author><author>Neuhard, Robert M.</author><author>Scioscia, Angela L.</author><author>Satterlund, Alysson M.</author><author>Simmons, Elizabeth H.</author><author>Abelman, Dismas B.</author><author>Brenner, David</author><author>Bruner, Judith C.</author><author>Buckley, Anne</author><author>Ellison, Michael</author><author>Gattas, Jeffrey</author><author>Gonias, Steven L.</author><author>Hale, Matt</author><author>Hawkins, Faith</author><author>Ikeda, Lydia</author><author>Jhaveri, Hemlata</author><author>Johnson, Ted</author><author>Kellen, Vince</author><author>Kremer, Brendan</author><author>Matthews, Gary</author><author>McLawhon, Ronald W.</author><author>Ouillet, Pierre</author><author>Park, Daniel</author><author>Pradenas, Allorah</author><author>Reed, Sharon</author><author>Riggs, Lindsay</author><author>Sanders, Alison</author><author>Sollenberger, Bradley</author><author>Song, Angela</author><author>White, Benjamin</author><author>Winbush, Terri</author><author>Aceves, Christine M.</author><author>Anderson, Catelyn</author><author>Gangavarapu, Karthik</author><author>Hufbauer, Emory</author><author>Kurzban, Ezra</author><author>Lee, Justin</author><author>Matteson, Nathaniel L.</author><author>Parker, Edyth</author><author>Perkins, Sarah A.</author><author>Ramesh, Karthik S.</author><author>Robles-Sikisaka, Refugio</author><author>Schwab, Madison A.</author><author>Spencer, Emily</author><author>Wohl, Shirlee</author><author>Nicholson, Laura</author><author>Mchardy, Ian H.</author><author>Dimmock, David P.</author><author>Hobbs, Charlotte A.</author><author>Bakhtar, Omid</author><author>Harding, Aaron</author><author>Mendoza, Art</author><author>Bolze, Alexandre</author><author>Becker, David</author><author>Cirulli, Elizabeth T.</author><author>Isaksson, Magnus</author><author>Schiabor Barrett, Kelly M.</author><author>Washington, Nicole L.</author><author>Malone, John D.</author><author>Schafer, Ashleigh Murphy</author><author>Gurfield, Nikos</author><author>Stous, Sarah</author><author>Fielding-Miller, Rebecca</author><author>Garfein, Richard S.</author><author>Gaines, Tommi</author><author>Anderson, Cheryl</author><author>Martin, Natasha K.</author><author>Schooley, Robert</author><author>Austin, Brett</author><author>MacCannell, Duncan R.</author><author>Kingsmore, Stephen F.</author><author>Lee, William</author><author>Shah, Seema</author><author>McDonald, Eric</author><author>Yu, Alexander T.</author><author>Zeller, Mark</author><author>Fisch, Kathleen M.</author><author>Longhurst, Christopher</author><author>Maysent, Patty</author><author>Pride, David</author><author>Khosla, Pradeep K.</author><author>Laurent, Louise C.</author><author>Yeo, Gene W.</author><author>Andersen, Kristian G.</author><author>Knight, Rob</author></authors></contributors><titles><title>Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission</title><secondary-title>Nature</secondary-title></titles><periodical><full-title>Nature</full-title></periodical><pages>1-4</pages><keywords><keyword>Environmental biotechnology</keyword><keyword>Genome informatics</keyword><keyword>Phylogenetics</keyword><keyword>SARS-CoV-2</keyword><keyword>Viral infection</keyword></keywords><dates><year>2022</year><pub-dates><date>2022-07-07</date></pub-dates></dates><isbn>1476-4687</isbn><electronic-resource-num>10.1038/s41586-022-05049-6</electronic-resource-num><abstract>As SARS-CoV-2 continues to spread and evolve, detecting emerging variants early is critical for public health interventions. Inferring lineage prevalence by clinical testing is infeasible at scale, especially in areas with limited resources, participation, or testing/sequencing capacity, which can also introduce biases1‚Äì3. SARS-CoV-2 RNA concentration in wastewater successfully tracks regional infection dynamics and provides less biased abundance estimates than clinical testing4,5. Tracking virus genomic sequences in wastewater would improve community prevalence estimates and detect emerging variants. However, two factors limit wastewater-based genomic surveillance: low-quality sequence data and inability to estimate relative lineage abundance in mixed samples. Here, we resolve these critical issues to perform a high-resolution, 295-day wastewater and clinical sequencing effort, in the controlled environment of a large university campus and the broader context of the surrounding county. We develop and deploy improved virus concentration protocols and deconvolution software that fully resolve multiple virus strains from wastewater. We detect emerging variants of concern up to 14 days earlier in wastewater samples, and identify multiple instances of virus spread not captured by clinical genomic surveillance. Our study provides a scalable solution for wastewater genomic surveillance that allows early detection of SARS-CoV-2 variants and identification of cryptic transmission.</abstract><remote-database-name>www.nature.com</remote-database-name><language>en</language><urls><web-urls><url>https://www.nature.com/articles/s41586-022-05049-6</url></web-urls><pdf-urls><url>C:\Users\bcalverley\Zotero\storage\7BZZ3FUG\Karthikeyan et al__Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission__2022.pdf</url></pdf-urls><text-urls><url>C:\Users\bcalverley\Zotero\storage\ZMN9CZXC\s41586-022-05049-6.html</url></text-urls></urls><access-date>2022-07-22 21:41:10</access-date></record><record><database name="MyLibrary">MyLibrary</database><source-app name="Zotero">Zotero</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Tuekprakhon, Aekkachai</author><author>Nutalai, Rungtiwa</author><author>Dijokaite-Guraliuc, Aiste</author><author>Zhou, Daming</author><author>Ginn, Helen M.</author><author>Selvaraj, Muneeswaran</author><author>Liu, Chang</author><author>Mentzer, Alexander J.</author><author>Supasa, Piyada</author><author>Duyvesteyn, Helen M. E.</author><author>Das, Raksha</author><author>Skelly, Donal</author><author>Ritter, Thomas G.</author><author>Amini, Ali</author><author>Bibi, Sagida</author><author>Adele, Sandra</author><author>Johnson, Sile Ann</author><author>Constantinides, Bede</author><author>Webster, Hermione</author><author>Temperton, Nigel</author><author>Klenerman, Paul</author><author>Barnes, Eleanor</author><author>Dunachie, Susanna J.</author><author>Crook, Derrick</author><author>Pollard, Andrew J.</author><author>Lambe, Teresa</author><author>Goulder, Philip</author><author>Paterson, Neil G.</author><author>Williams, Mark A.</author><author>Hall, David R.</author><author>Conlon, Christopher</author><author>Deeks, Alexandra</author><author>Frater, John</author><author>Frending, Lisa</author><author>Gardiner, Siobhan</author><author>J√§ms√©n, Anni</author><author>Jeffery, Katie</author><author>Malone, Tom</author><author>Phillips, Eloise</author><author>Rothwell, Lucy</author><author>Stafford, Lizzie</author><author>Fry, Elizabeth E.</author><author>Huo, Jiandong</author><author>Mongkolsapaya, Juthathip</author><author>Ren, Jingshan</author><author>Stuart, David I.</author><author>Screaton, Gavin R.</author></authors></contributors><titles><title>Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum</title><secondary-title>Cell</secondary-title></titles><periodical><full-title>Cell</full-title><abbr-1>Cell</abbr-1></periodical><pages>2422-2433.e13</pages><volume>185</volume><number>14</number><issue>14</issue><keywords><keyword>antibody escape</keyword><keyword>BA.4</keyword><keyword>BA.5</keyword><keyword>COVID-19</keyword><keyword>Omicron</keyword><keyword>SARS-CoV-2</keyword><keyword>variant</keyword><keyword>VoC</keyword></keywords><dates><year>2022</year><pub-dates><date>2022-07-07</date></pub-dates></dates><isbn>0092-8674</isbn><electronic-resource-num>10.1016/j.cell.2022.06.005</electronic-resource-num><abstract>The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa‚Äôs Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.</abstract><remote-database-name>ScienceDirect</remote-database-name><language>en</language><urls><web-urls><url>https://www.sciencedirect.com/science/article/pii/S0092867422007103</url></web-urls><pdf-urls><url>C:\Users\bcalverley\Zotero\storage\368WI6R7\Tuekprakhon et al__Antibody escape of SARS-CoV-2 Omicron BA__2022.pdf</url></pdf-urls><text-urls><url>C:\Users\bcalverley\Zotero\storage\5QMNCVUI\S0092867422007103.html</url></text-urls></urls><access-date>2022-07-22 21:41:35</access-date></record><record><database name="MyLibrary">MyLibrary</database><source-app name="Zotero">Zotero</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Rahimi, Farid</author><author>Talebi Bezmin Abadi, Amin</author></authors></contributors><titles><title>The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic</title><secondary-title>International Journal of Surgery (London, England)</secondary-title><short-title>The Omicron subvariant BA.2</short-title></titles><periodical><full-title>International Journal of Surgery (London, England)</full-title><abbr-1>Int J Surg</abbr-1></periodical><pages>106261</pages><volume>99</volume><dates><year>2022</year><pub-dates><date>2022-3</date></pub-dates></dates><isbn>1743-9191</isbn><electronic-resource-num>10.1016/j.ijsu.2022.106261</electronic-resource-num><remote-database-name>PubMed Central</remote-database-name><urls><web-urls><url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837492/</url></web-urls><text-urls><url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837492/</url></text-urls></urls><access-date>2022-07-22 22:07:17</access-date></record></records></xml>